Objectives: To evaluate the safety and efficacy of weekly docetaxel with capecitabine in patients with recurrent/persistent epithelial ovarian cancer (EOC).
Patients And Methods: Women treated for recurrent/persistent EOC in our department (January 2004 through December 2005) were recruited into this feasibility study. They received 35 mg/m(2) docetaxel on days 1 and 8 and 1,000 mg/m(2) capecitabine twice daily on days 1-14 in a 21-day cycle.
Results: Nine patients were enrolled. The median age was 64 years (37-80). Time to progression ranged from 1.67 to 11.27 months: 1 had complete response, 3 had partial responses, 4 had stable disease and 1 had disease progression. There was no grade 3 or 4 bone marrow toxicity. Nonhematological toxicity included partial hair loss (n = 4), fatigue (n = 7), hand and foot syndrome (n = 2), diarrhea (n = 5) and fluid retention syndrome (n = 1).
Conclusion: There was good antitumor activity but frequent moderate-to-severe nonhematological toxicities when weekly docetaxel and capecitabine were used as second-line therapy for recurrent EOC. Further investigation of this combination is warranted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000224658 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Superior 125-month outcome through cetuximab in the larynx organ preservation trial DeLOS-II: a single study center's experience.
Front Oncol
December 2024
Clinic for Otorhinolaryngology, University Hospital Leipzig, Leipzig, Germany.
Introduction: The larynx organ preservation (LOP) trial DeLOS-II enrolled = 173 patients with advanced laryngeal/hypopharyngeal squamous cell carcinoma (LHSCC) amenable (only curatively resectable) through total laryngectomy (TL) to receive induction chemotherapy (IC) with TPF [docetaxel (T), cisplatin (P), and 5-fluorouracil (F)] (arm A, 85 patients) or additional cetuximab (E) weekly (arm B, 88 patients). Responders with endoscopic estimated tumor surface shrinkage (ETSS) ≥30% after 1 cycle IC (IC-1) received a further two cycles of IC followed by radiotherapy (RT), whereas TL was recommended for non-responders. Arm B failed to show superior 24-month laryngectomy-free survival (LFS) and overall survival (OS), the protocol-specified primary and secondary endpoints.
View Article and Find Full Text PDFSequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma.
Cancers (Basel)
December 2024
Department of Urology, University of Iowa, Iowa City, IA 52242, USA.
After first-line treatment failure, patients with non-muscle invasive urothelial carcinoma (NMIUC) are recommended to undergo radical cystectomy. However, those unable to pursue radical surgery or desiring bladder preservation require effective salvage therapies. Multi-agent treatment regimens are particularly useful for targeting the complex resistance mechanisms of recurrent UC.
View Article and Find Full Text PDFWeekly versus 2-weekly versus 3-weekly docetaxel to treat metastatic castration-resistant prostate cancer.
Prostate Int
December 2024
Department of Internal Urology, College of Medicine, Seoul National University, Seoul, Korea.
Background: To compare the efficacy and toxicity of docetaxel treatment regimens in metastatic castration-resistant prostate cancer (mCRPC).
Methods: We retrospectively analyzed 162 patients diagnosed with mCRPC who underwent docetaxel chemotherapy between 2009 and 2020. The patients were divided into three groups according to the dosage and interval of docetaxel (DCT) chemotherapy regimen: 30 mL/m weekly, 50 mL/m biweekly (every 2 weeks), and 75 mL/m triweekly (every 3 weeks).
Phase 1/2 trial of XPO1 inhibitor selinexor plus docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer.
Clin Cancer Res
December 2024
The University of Texas Southwestern Medical Center, Dallas, Texas, United States.
Purpose: Patients with KRAS mutant non-small cell lung cancer (NSCLC) have limited therapeutic options. Based on activity of nuclear export inhibition in preclinical models, we evaluated this strategy in previously treated advanced KRAS mutant NSCLC.
Patients And Methods: The primary outcome of this multi-center phase 1/2 dose escalation trial of selinexor plus docetaxel was safety and tolerability.
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial.
Lancet Oncol
January 2025
Department of Breast Disease, Henan Breast Cancer Centre, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China. Electronic address:
Article Synopsis
- The study aimed to compare the effectiveness of weekly nab-paclitaxel versus the standard treatment of docetaxel plus carboplatin, both combined with trastuzumab and pertuzumab, for patients with HER2-positive early-stage breast cancer.
- HELEN-006 was a phase 3 trial conducted across six hospitals in China, enrolling 689 patients with untreated, confirmed stage II-III HER2-positive breast cancer, who were randomly assigned to one of the two treatment groups.
- The trial's final analysis focused on the primary endpoint of pathological complete response, with ongoing follow-up for the adjuvant phase, and the trial is registered under ClinicalTrials.gov (NCT04547907).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!